Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Short-term Investments (2020 - 2025)

Historic Short-term Investments for Protalix BioTherapeutics (PLX) over the last 6 years, with Q3 2025 value amounting to $15.7 million.

  • Protalix BioTherapeutics' Short-term Investments changed N/A to $15.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year change of. This contributed to the annual value of $15.1 million for FY2024, which is 2798.43% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Short-term Investments stood at $15.7 million for Q3 2025.
  • Protalix BioTherapeutics' Short-term Investments' 5-year high stood at $50.6 million during Q1 2021, with a 5-year trough of $5.1 million in Q4 2022.
  • In the last 5 years, Protalix BioTherapeutics' Short-term Investments had a median value of $16.1 million in 2022 and averaged $21.7 million.
  • In the last 5 years, Protalix BioTherapeutics' Short-term Investments plummeted by 7345.66% in 2022 and then skyrocketed by 31282.3% in 2023.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Short-term Investments stood at $38.0 million in 2021, then plummeted by 86.67% to $5.1 million in 2022, then surged by 312.82% to $20.9 million in 2023, then decreased by 27.98% to $15.1 million in 2024, then grew by 4.33% to $15.7 million in 2025.
  • Its last three reported values are $15.7 million in Q3 2025, $15.5 million for Q2 2025, and $15.3 million during Q1 2025.